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Genomewide association studies (GWAS) are becoming an im-
portant part of the human genetics research landscape. As the
technological and analytical tools have been developed, many of
the National Institutes of Health (NIH) centers and institutes
have launched projects to ﬁnd genes or sets of genes that con-
tribute to a variety of human disorders. Massive data sets are
required to perform comprehensive genotype-phenotype analy-
ses. GWAS projects that have been launched by the NIH include
the Genetic Association Information Network (GAIN) (http://
www.fnih.org/GAIN/GAIN_home.shtml) and the Genes and En-
vironment Initiative (GEI) (http://www.gei.nih.gov). Because the
NIH is the steward of the public’s investment in biomedical re-
search, the NIH created a mechanism (i.e., a data repository) and
related policy tomaximize data sharing among the scientiﬁc com-
munity. The draft policy includes the following major elements:
data management (i.e., protection of research subjects, data sub-
mission procedures, and data access principles), scientiﬁc publi-
cation, and intellectual property. The draft policy is available at
http://grants2.nih.gov/grants/gwas/.
GWAS Data Management Overview
The proposed federal policy calls for NIH-funded investigators to
submit to a data repository GWAS genotype and phenotype data
that have been deidentiﬁed and uniquely coded by the primary
investigators. They would also be required to submit documen-
tation that describes how the conﬁdentiality of research subjects
is protected, project protocols, and data variable descriptions. Ac-
cess to the repository would be granted by anNIH-appointedData
Access Committee, which would review all applicant projects and
put data-use agreements in place. Publication exclusivity would
last for 9 months, after which subsequent secondary analyses
would be required to acknowledge the original contributors of
the data and funding organizations. Consistent with other NIH
policies, the broad use and sharing of data are encouraged, and
the submission of premature intellectual property claims on pre-
competitive information is discouraged.
The Challenge to the Scientiﬁc Community
The draft policy was made available for public comment through
October 2006. The leadership of the American Society of Human
Genetics (ASHG) had initiated a draft response, and then, at the
ASHG Business Meeting in New Orleans, members of the Society
raised serious concerns about the draft policy. ASHG immedi-
ately requested an extension of the comment deadline, and the
NIH responded with an extension to November 30, 2006. Presi-
dent Steve Warren appointed a small working group to draft the
Society’s comments, and then the leadership reviewed and ap-
proved the response that was submitted to the NIH.
ASHG’s Response
The Request for Information (RFI) from the NIH was structured
as a set of questions, and the complete ASHG response is avail-
able on the Web site at http://www.ashg.org/genetics/ashg/news/
gwas.shtml. The major points are summarized below.
1. ASHG supports the concept of data sharing and the devel-
opment of a centralized repository, but this support is contin-
gent on there being changes made to the proposed policy, as
suggested below, as well as the addition of clarifying state-
ments and additional scientiﬁc consultation.
2. There remain substantial risks to research subject protection
with the policy as proposed, since the combination of geno-
type and signiﬁcant phenotypic data remains a potentially
accurate and unique identiﬁer, even if names and Social Se-
curity numbers are removed. We remain concerned that
enough information would be available to lead to the iden-
tiﬁcation of speciﬁc individuals and their relatives, even with
the controls deﬁned. Therefore, the data access certiﬁcation
process must be rigorous, and any misuse of data must have
clear and important consequences.
3. Because institutional review boards (IRBs) have great variabil-
ity in their responses to federal guidelines and policy, more
clariﬁcation of and speciﬁcation in the language required to
protect subjects is necessary. This speciﬁcity and additional IRB
training would be helpful for both data depositors and reques-
tors. Informed consent with wide data-sharing provisionsmay
be appropriate for future studies but is not a pragmatic solution
for existing studies that may require reconsent.
4. ASHG is assuming that the repository process would be funded
by intramural funds and would not adversely impact extra-
mural funding. If this is not the case, then serious concerns
remain in the prioritization of research endeavors. In addi-
tion, investigators may require additional funding to meet re-
quirements for data preparation and transfer to the repository,
as well as additional resources for any process of requisite
reconsent.
5. Unlike the more regular features of molecular (sequence and
polymorphism) data, the challenges of obtaining and curating
phenotypic variate and covariate data, as well as exposures,
are not trivial. Variable deﬁnitions and protocol differences
may require extensive interpretation before meaningful anal-
ysis. In addition, the presentation of precomputed simple com-
parisons may be misleading and produce inaccurate results,
and interpretations of secondary analyses may be incomplete
or derive inappropriate conclusions.
6. ASHG urged the NIH to engage in more discussion with rep-
resentatives of the extramural as well as the intramural sci-
entiﬁc and advocacy communities before ﬁnalizing the policy.
The suggestion was made to perform a pilot test of contributed
data, to assess the implications before taking the policy public.
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In December, the NIH held a town hall meeting, presenting an
additional overview of the policy and brieﬂy summarizing some
of the issues raised in the comments. Earlier the same week, an
announcement had been made that the National Center for Bio-
technology Information had developed unique databases tomake
the results of GWAS widely available to the research community,
such as the results on macular degeneration and Parkinson dis-
ease that can be accessed at the dbGaP Web site (http://www
.ncbi.nih.gov/entrez/query.fcgi?dbpgap). Until scientists have
the opportunity to examine and evaluate the database, further
reasoned comments cannot appropriately be made.
Now What?
Although ASHG was pleased to have the opportunity to respond
to a formal RFI during a public comment period, major challen-
ges clearly remain with the steps taken in a complicated process
that may implicate major changes in the clinical genetics and
genetic epidemiology communities. ASHG members should stay
informed of changes and possible opportunities to remain en-
gaged in this policy process.
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